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The direct lineage reprogramming of one specialized cell type into another using defined factors has funda-
mentally re-shaped traditional concepts regarding the epigenetic stability of differentiated cells. With the
rapid increase in cell types generated through direct conversion in recent years, this strategy has become
a promising approach for producing functional cells. Here, we review recent advances in lineage reprogram-
ming, including the identification of novel reprogramming factors, underlying molecular mechanisms, strate-
gies for generating functionally mature cells, and assays for characterizing induced cells. We also discuss
progress toward the application of lineage reprogramming and the major future challenges for this strategy.Introduction
The generation of desired functional cell types is a long-standing
major goal of regenerative medicine, which holds great promise
for biomedical applications. Although conventional strategies,
particularly the directed differentiation of pluripotent stem cells,
have been extensively studied for this purpose and have pro-
gressed rapidly in recent years (Murry and Keller, 2008; Tabar
and Studer, 2014), there has also been great interest in the devel-
opment of alternative strategies for obtaining functional cells. In
principle, lineage reprogramming, which can be defined as the
direct induction of functional cell types from one lineage to
another lineage without passing through an intermediate plurip-
otent stage (Graf and Enver, 2009), could become an alternative
way to produce the desired cell types. The feasibility of this strat-
egy was first demonstrated by the conversion of fibroblasts into
myoblasts by overexpressingMyod, which led to the conceptual
breakthrough that a single cell-type-specific transcription factor
can change cell fate (Davis et al., 1987). Subsequent studies
showed that transcription factor-driven cell fate conversion
could be achieved between related lineages such as different
cell types within the blood, endoderm, and nervous system
(Heins et al., 2002; Kulessa et al., 1995; Shen et al., 2000; Xie
et al., 2004).
The advent of induced pluripotent stem cells (iPSCs), which
demonstrates that a combination of cell-type-specific transcrip-
tion factors can change cell fates between developmentally
distant cell types, has reignited the field of lineage reprogram-
ming (Takahashi and Yamanaka, 2006). The use of transcription
factor combinations was quickly applied to the in vivo generation
of pancreatic insulin-producing cells that alleviated hyperglyce-
mia in diabetic mouse models (Zhou et al., 2008). Subsequently,
the induction of neuronal cells by transcription factors proved
that lineage conversion could be conducted across distant
germ layers (Vierbuchen et al., 2010). Since then, lineage reprog-
ramming using transcription factor combinations has also beenused to induce several other cell types, such as cardiomyocytes
and hepatocytes (Huang et al., 2011; Ieda et al., 2010; Sekiya
and Suzuki, 2011). Inspiringly, this field has progressed rapidly
in recent years, which has resulted not only in the identification
of novel reprogramming factors but also the development of
new strategies to improve the functional maturation of converted
cells. As a result, the number of different cell types derived from
lineage reprogramming in both mice and humans has substan-
tially increased (Figure 1; Tables 1 and 2). Based on these recent
advances, lineage reprogramming has become a widely used
and promising approach for obtaining functional cell types. In
this review, we discuss the major aspects of the recent progress
in direct lineage reprogramming and provide perspectives for
future challenges in the field.
Beyond Lineage-Specific Transcription Factor
Overexpression: Novel Factors Involved in Lineage
Reprogramming
Although the enforced expression of transcription factors has
been extensively used to induce lineage conversion in multiple
studies (Tables 1 and 2), there is still great interest in the identi-
fication of other factors capable of inducing lineage conversion.
Notably, recent findings have indicated that alternative factors,
including epigenetic regulators, microRNAs (miRNAs), and small
molecules, have been implicated in lineage reprogramming
(Figure 2). Importantly, the understanding of the molecular
mechanisms underlying lineage reprogramming could poten-
tially benefit from these studies. Furthermore, these novel factors
may represent alternative ways of achieving cell fate conversion
in the future.
Epigenetic Regulators. Fundamentally, lineage reprogramming
involves the transition between different epigenetic states. In
addition, during lineage reprogramming, exogenous factors
must interact with or act upon epigenetic regulators to properly
reactivate the epigenetically repressed state of the target cell-
type-specific master genes. Therefore, it is reasonable thatCell Stem Cell 16, February 5, 2015 ª2015 Elsevier Inc. 119
Figure 1. Historical View of the Development of Lineage Reprogramming
Selected advances in the development of lineage reprogramming are highlighted in different colors. Green, blue, and red indicate the induction of terminally
differentiated cell types, stem cells or progenitors/precursors, and in vivo lineage reprogramming, respectively. Texts above the timeline indicate studies in mice,
and texts below the timeline indicate studies in humans.
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of this notion, it has been reported that non-cardiac mesoderm
in mouse embryos could be transdifferentiated into cardiomyo-
cytes by the ectopic expression of the cardiac transcription fac-
tors Gata4 and Tbx5 in combination with the cardiac-specific
subunit of BAF chromatin remodeling complexes, which are
referred to as Baf60c. Mechanistically, the essential role of
Baf60c during this conversion can be explained, in part, by
permitting the binding of Gata4 to cardiac genes (Takeuchi and
Bruneau, 2009).
Such studies illustrate that chromatin remodelers can facili-
tate lineage conversion through coordination with exogenous
transcription factors; however, epigenetic barriers mediated
by chromatin modifiers can also hinder lineage reprogramming.
Epigenetic barriers during iPSC reprogramming have been
extensively characterized (Buganim et al., 2013; Theunissen
and Jaenisch, 2014), and some of the same barriers may
also play a role in lineage reprogramming. For example, the
inhibition or removal of chromatin modifiers such as histone
deacetylases and polycomb repressor complex 2 (PRC2) can
facilitate the conversion of germ cells to neurons driven by
neuron-specific transcription factors in Caenorhabditis elegans
(Patel et al., 2012; Tursun et al., 2011). Together, these findings
indicate a complicated interaction between epigenetic regula-
tors and extrinsic lineage-specific factors during lineage
conversion.
The importance of epigenetic regulators during lineage re-
programming is further highlighted by the interesting fact that
lineage conversion can occur through the manipulation of epige-
netic regulators alone. In mice, a DNA methyltransferase Dnmt1
deficiency in pancreatic b cells leads to their conversion into a
cells (Dhawan et al., 2011). Further analysis indicated that Arx,
a master gene responsible for the maintenance of a cell identity,
was re-activated in b cells uponDnmt1mutation (Courtney et al.,
2013). Therefore, the disruption of DNA methylation may re-acti-120 Cell Stem Cell 16, February 5, 2015 ª2015 Elsevier Inc.vate certain lineage-specific master genes that are sufficient to
direct cell fates. In addition to the disruption of DNAmethylation,
the manipulation of histone-modifying enzymes may affect the
lineage conversion process, because these histone modifica-
tions also correspond to transcriptionally active or silent chro-
matin states (Jenuwein and Allis, 2001). In Caenorhabditis
elegans, it has recently been reported that the histone
H3K27me2/3 demethylase Jmjd3.1 and the H3K4 methyltrans-
ferase Set1 complex can sequentially determine the transdiffer-
entiation of hindgut cells into motor neurons (Zuryn et al., 2014).
Several important questions have emerged from studies that
manipulate epigenetic regulators to induce lineage reprogram-
ming. First, many of these studies have relied upon analyzing
marker gene expression rather than functional output to charac-
terize the identity of converted cells. Therefore, it is still unclear if
functionally mature cells can be obtained using epigenetic regu-
lators. Second, most of these conversions were conducted
in vivo, and whether epigenetic regulators can function like tran-
scription factors that induce lineage conversion in vitro remains
unclear. Finally, questions regarding the mechanisms and spec-
ificity of action remain unanswered. In general, current studies
support that two types of epigenetic regulators are involved in
lineage reprogramming: one expressed specifically in certain lin-
eages and the other expressed more broadly in different cell
types. Although several studies have shown that lineage-specific
epigenetic regulators may exert their function by specifically
modulating the epigenetic state of lineage-specific genes (Take-
uchi and Bruneau, 2009), it remains largely unknown how the
manipulation of universal epigenetic regulators activates the
core gene regulatory network (GRN), especially transcription
factors whose expression is specific to the target cell type.
One possibility is that they may drive the lineage conversion in
a context-dependent manner; that is, their function relies on
signaling pathways and transcription factors already present in
the starting population. Understanding these interactions may
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promoting lineage reprogramming.
miRNAs. Emerging evidence indicates that miRNAs are impor-
tant players in lineage reprogramming. For induced neuronal (iN)
cell induction, the overexpression of the neuronal-specific
miRNAs miR-9/9* and miR-124 alone in human fibroblasts can
induce neuron-like cells that express the neuronal marker
MAP2; however, the addition of transcription factors is required
for functional human iN cell formation (Yoo et al., 2011). In
another study, the overexpression of miR-124 also promoted
human iN cell induction mediated via BRN2 andMYT1L overex-
pression (Ambasudhan et al., 2011). In addition to iN cell induc-
tion, miRNA-driven cardiac lineage conversion can be induced
in vitro and in vivo via the use of cardiac enriched miRNAs
miR-1, miR-133, miR-208, and miR-499 alone (Jayawardena
et al., 2012). The substantial role of miRNAs in lineage reprog-
ramming has been further revealed by the surprising fact that
the induction of functional murine iN cells can be achieved via
the inhibition of the miRNA regulator PTB alone (Xue et al.,
2013). PTB blocks miRNA-mediated activity of the REST com-
plex, thus PTB inhibition promotes iN cell induction by allowing
de-repression of multiple miRNA-regulated neuronal genes.
In general, it seems that miRNA-induced lineage conversion is
currently still not as efficient as transcription-factor-mediated
lineage conversion. For instance, the enforced overexpression
of miRNAs alone only induces neural marker gene expression
in human non-neural cells (Ambasudhan et al., 2011; Yoo
et al., 2011), which was in contrast to the relatively complete in-
duction of functional human neuronal cells by transcription fac-
tors (Pang et al., 2011). While PTB inhibition leads to functional
neuronal induction in mice (Xue et al., 2013), it is possible that
mechanisms other than miRNA regulation may also be involved
in neuronal induction triggered by PTB inhibition. For example,
inhibition of the REST complex, which was thought to be an
important player in the PTB-regulated miRNA program in
neuronal induction, cannot fully recapitulate the effects of PTB
inhibition (Xue et al., 2013). It is possible that alternative splicing
is also involved, because PTB is a well-known splicing regulator
(Oberstrass et al., 2005). While the reported miRNA-mediated
lineage conversions need to be further confirmed, it is also
important to determine whether the overexpression of exoge-
nous miRNAs alone is sufficient to induce functional converted
cells either in vitro or in vivo.
Although current studies provide insight into miRNA-mediated
cell fate conversion, the molecular mechanisms of this process
remain elusive. Considering that miRNAs typically regulate their
targets through repression (Bartel, 2009), how miRNAs activate
master gene expression for a target cell type is an appealing
question. One possibility is that the overexpression of lineage-
specific miRNAs may downregulate master regulators that are
expressed in the initial cells or the transition cells, which may
lead to the disruption of balance among master regulators of
different lineages. For example, it has been reported that
neuronal-specific miR-124a decreases the levels of hundreds
of non-neuronal transcripts even when expressed in non-neural
cells (Lim et al., 2005). This inhibition may also inhibit non-
neuronal master genes and shift the balance toward the expres-
sion of neuronal master genes, thus pushing the cells toward
neural conversion. Another possibility is that miRNAsmay down-regulate the expression of certain epigenetic regulators and pro-
mote the global epigenetic changes in certain in vitro or in vivo
contexts. For example, miR-124 directly regulates the expres-
sion of Ezh2, a histone H3 Lys-27 histone methyltransferase,
which facilitates the expression of neural-specific Ezh2 target
genes (Neo et al., 2014). While these possibilities still need to
be confirmed by experimental evidence, studies revealing how
miRNA-induced lineage conversion occurs could deepen the
broader understanding of mechanisms underlying lineage re-
programming.
Small Molecules. The use of genetic manipulation in lineage re-
programming raises safety concerns for its clinical applications,
and one of themost promising potential solutions is the induction
of this conversion by small molecules. Small molecules have
several prominent advantages over traditional methods for regu-
lating cell fate: they can be cell permeable; more cost-effective;
andmore easily synthesized, preserved, and standardized. More
importantly, the effects of small molecules can be fine-tuned by
varying their concentrations and combinations, thus providing a
higher degree of temporal and spatial control over protein func-
tion (Li et al., 2013b). Small molecules have been widely used in
iPSC reprogramming (Li et al., 2013b). Remarkably, iPSCs could
be generated using the combinations of small molecules alone
(Hou et al., 2013). Recently, several small molecules have been
reported to promote the efficiency of neural conversion, to
reduce the requirement for exogenous factors, or to directly
induce cell fate conversion (Cheng et al., 2014; Kim et al.,
2014; Ladewig et al., 2012; Liu et al., 2013; Sayed et al., 2015;
Zhu et al., 2014a). However, identifying small molecules that
completely replace exogenous transcription factors during
lineage reprogramming remains a major challenge for most
lineages.
Natural examples of dedifferentiation or transdifferentiation
processes have been observed in several vertebrate species
(Jopling et al., 2011) and can provide insight on identifying small
molecules that could modulate these pathways. In principle, the
transition between different cellular states is the output of inter-
actions among multiple factors such as signal pathways, tran-
scription factors, and epigenetic regulators, and signal pathways
and epigenetic regulators are involved in these natural lineage
conversions. For instance, Wnt signaling has been shown to
play a deterministic role during lens regeneration in adult newts
(Hayashi et al., 2006), which involves the conversion of pig-
mented epithelial cells to lens cells. Epigenetic modifiers such
as histone deacetylases are also reported to be upregulated dur-
ing this process (Maki et al., 2010). These natural examples sug-
gest the possibility of manipulating signaling pathways and
epigenetic regulators to induce lineage conversion, and this
could theoretically be achieved by small molecules that modu-
late these pathways and factors, which is indeed the case for
chemical iPSC induction (Hou et al., 2013). Furthermore, for suc-
cessful chemically induced lineage conversion, careful titration
of the dosage and duration of different small molecules may be
critical. For instance, to activate endogenous Oct4 activity, the
SAH hydrolase inhibitor 3-deazaneplanocin A (DZNep) could
only be added during the late stage of chemical reprogramming
(Hou et al., 2013).
Another intriguing question is how small molecules could
replace the function of exogenous transcription factors duringCell Stem Cell 16, February 5, 2015 ª2015 Elsevier Inc. 121
Table 1. Summary of Lineage Reprogramming in Mice since the Discovery of iPSCs
In Vitro or
In Vivo Initial Cell Population Target Cell Type Reprogramming Factors Reference
In vitro Fibroblasts Adipocytes (brown fat cells) PRDM16, CEBPb Kajimura et al., 2009
In vitro Fibroblasts Astrocytes Nfia, Nfib, Sox9 Caiazzo et al., 2014
Both Fibroblasts Cardiomyocytes Gata4, Hand2, Mef2c, Tbx5 Song et al., 2012
Both Fibroblasts Cardiomyocytes miR-1, miR-133, miR-208, miR-499,
JAK inhibitor I
Jayawardena et al., 2012
In vitro Fibroblasts Cardiomyocytes Gata4, Mef2c, Tbx5 Ieda et al., 2010
In vitro Fibroblasts Cardiomyocytes Hand2, Nkx2.5, Gata4, Mef2c, Tbx5 Addis et al., 2013
In vitro Fibroblasts Cardiomyocytes Mef2c, Myocd, Tbx5 Protze et al., 2012
In vitro Fibroblasts Cardiomyocytes MYOCD, SRF, Mesp1, GATA4,
TBX5, MEF2C, SMARCD3
Christoforou et al., 2013
In vivo Fibroblasts Cardiomyocytes Gata4, Mef2c, Tbx5 Qian et al., 2012
In vivo Fibroblasts Cardiomyocytes Gata4, Mef2c, Tbx5 Inagawa et al., 2012
In vitro Fibroblasts Chondrocytes Sox9, Klf4, c-Myc Hiramatsu et al., 2011
In vivo Rod photoreceptors Cone-like cells Nrl ablation Montana et al., 2013
In vitro Fibroblasts Endothelial cells Foxo1, Er71, Klf2, Tal1, Lmo2 Han et al., 2014
In vitro Fibroblasts Hemogenic endothelial-like
precursor cells
Gata2, Gfi1b, cFos, Etv6 Pereira et al., 2013
In vitro Fibroblasts Haematopoietic progenitor cells ERG, GATA2, LMO2, RUNX1c, SCL,
p53(/)
Batta et al., 2014
In vivo Committed lymphoid,
myeloid progenitors, and
myeloid effector cells
Haematopoietic stem cells Run1t1, Hlf, Lmo2, Prdm5, Pbx1,
Zfp37, Mycn, Meis1
Riddell et al., 2014
In vitro Fibroblasts Hepatic stem cells Hnf1b, Foxa3 Yu et al., 2013
In vitro Fibroblasts Hepatocytes Gata4, Hnf1a, Foxa3, P19ARF
knockdown
Huang et al., 2011
In vitro Fibroblasts Hepatocytes Hnf4a plus Foxa1, Foxa2 or Foxa3 Sekiya and Suzuki, 2011
In vivo Layer II/III callosal
projection neurons
Layer-V/VI corticofugal projection
neurons
Fezf2 Rouaux and Arlotta, 2013
In vitro Fibroblasts Macrophages PU.1 plus CEBPa or CEBPb Feng et al., 2008
In vitro B cells Macrophages CEBPa Bussmann et al., 2009
In vitro Fibroblasts Melanocytes MITF, SOX10, PAX3 Yang et al., 2014
In vitro Neural stem cells Monocytes PU.1 Forsberg et al., 2010
In vivo T cells Natural killer-like cells Bcl11b deletion Li et al., 2010
In vitro Fibroblasts Neural precursor cells Brn2, Sox2, FoxG1 Lujan et al., 2012
In vitro Fibroblasts Neural progenitor cells VPA, CHIR99021, RepSox (616452)
under hypoxia
Cheng et al., 2014
In vitro Fibroblasts Neural stem cells Brn4, Sox2, Klf4, c-Myc, E47 Han et al., 2012
In vitro Fibroblasts Neural stem cells Sox2, Klf4,c-Myc, Oct4 (limiting
activity at initial stage)
Thier et al., 2012
In vitro Fibroblasts Neural stem cells Sox2 Ring et al., 2012
In vitro Sertoli cells Neural stem cells Ascl1, Ngn2, Hes1, Id1, Pax6, Brn2,
Sox2, c-Myc, Klf4
Sheng et al., 2012b
In vivo Astrocytes Neuroblasts Sox2 Niu et al., 2013
in vitro Hepatocytes Neurons Ascl1, Brn2, Myt1l Marro et al., 2011
In vitro Fibroblasts Neurons PTB repression Xue et al., 2013
In vitro Fibroblasts Neurons ASCL1 Chanda et al., 2014
In vivo Astrocytes Neurons Ascl1, Brn2, Myt1l Torper et al., 2013
In vivo Astrocytes Neurons (glutamatergic) NeuroD1 Guo et al., 2014
In vitro Fibroblasts Neurons (dopaminergic) Ascl1, Pitx3, Lmx1a, Nurr1, Foxa2, EN1 Kim et al., 2011b
In vitro Fibroblasts Neurons (dopaminergic) Ascl1, Lmx1a, Nurr1 Caiazzo et al., 2011
(Continued on next page)
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Table 1. Continued
In Vitro or
In Vivo Initial Cell Population Target Cell Type Reprogramming Factors Reference
In vitro Fibroblasts Neurons (dopaminergic) Lmx1a, Foxa2, Ascl1, Brn2 or
Lmx1b, Otx2, Nurr1, Ascl1, Brn2
Sheng et al., 2012a
In vitro Astrocytes Neurons (GABAergic) Ascl1, Dlx2 Heinrich et al., 2010
In vivo NG2 cells Neurons (glutamatergic and
GABAergic)
NeuroD1 Guo et al., 2014
In vitro Fibroblasts Neurons (glutamatergic) Ascl1, Brn2, Myt1l Vierbuchen et al., 2010
In vitro Astrocytes Neurons (glutamatergic) Ngn2 Heinrich et al., 2010
In vitro Fibroblasts Neurons (motor) Brn2, Ascl1, Myt1l, Lhx3, Hb9, Isl1,
Ngn2
Son et al., 2011
In vitro Fibroblasts Oigodendrocyte progenitor cells Olig1, Olig2, Nkx2.2, Nkx6.2, Sox10,
ST18, Gm98, Myt1
Najm et al., 2013
In vitro Fibroblasts Oligodendrocyte progenitor cells Sox10, Olig2, Zfp536 Yang et al., 2013
In vivo Hepatic progenitor cells Pancreatic islet cells Ngn3 Yechoor et al., 2009
In vivo Pancreatic b cells Pancreatic a cells Dnmt1 deficiency Dhawan et al., 2011
In vivo Pancreatic acinar cells Pancreatic a cells Ngn3, MafA Li et al., 2014b
In vivo Pancreatic acinar cells Pancreatic b cells Ngn3, Pdx1, MafA Zhou et al., 2008
In vivo Pancreatic acinar cells Pancreatic d cells Ngn3 Li et al., 2014b
In vitro Fibroblasts Sertoli cells Nr5a1, Wt1, Dmrt1, Gata4, Sox9 Buganim et al., 2012
In vivo Granulosa cells Sertoli cells Deletion of Foxl2 Uhlenhaut et al., 2009
In vitro Fibroblasts Thymic epithelial cells Foxn1 Bredenkamp et al., 2014
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global gene expression between different cell types may
involve thousands of genes, the core GRN that determines
one specific cell type may only be comprised of several master
genes. For example, a recent study indicated that the essential
transcription factor program of mouse naive pluripotent stem
cells involves 16 interactions, 12 components, and three inputs
(Dunn et al., 2014). Importantly, because there are multiple in-
teractions between factors of the core GRN, activation of
certain lineage-specific master genes may trigger feedback
that eventually activates the whole core GRN for a specific line-
age. Accordingly, activation of a few master genes for a spe-
cific lineage may prime cell fate conversion toward that lineage,
and functional induced cells could be generated with proper
culture conditions. Remarkably, small molecules could achieve
activation of certain factors such as transcription factors. For
example, small molecules could activate the expression of
two pluripotency genes Sall4 and Sox2, during the early phase
of chemical reprogramming (Hou et al., 2013). Another example
is the identification of a small molecule that activates the
expression of a critical pancreatic regulator PDX1 in human
ductal carcinoma cell lines and primary human islets (Yuan
et al., 2013). Considering that an important step during
transcription-factor-mediated lineage reprogramming is the
activation of the core GRN of the target cell type, small-mole-
cule-mediated activation of factors comprising the core GRN
may partially explain why small molecules could replace the
role of exogenous transcription factors during lineage conver-
sion. On the other hand, the exact mechanism of small-
molecule-mediated activation of factors comprising the core
regulatory network for a specific cell type remains elusive and
requires future studies.Pluripotency Factors for Indirect Lineage Reprogramming.
Recently, there has also been an increasing interest in the devel-
opment of an indirect lineage reprogramming strategy using plu-
ripotency factors. Several cell types havebeen inducedusing this
strategy, including cardiomyocytes (Efe et al., 2011), neural stem
cells or progenitors (Corti et al., 2012; Kim et al., 2011a; Thier
et al., 2012; Wang et al., 2013), pancreatic lineages (Li et al.,
2014a), angioblast-like progenitor cells (Kurian et al., 2013),
endothelial cells (Li et al., 2013a), and hepatocytes (Zhu et al.,
2014b) in either mouse or human cells. It has been proposed
that pluripotency-factor-driven lineage conversion is dependent
on the presence of an epigenetically unstable/plastic population
at early and intermediate stages during reprogramming, which
may be directed to an alternative cell fate other than iPSCs under
proper signaling environments (Ma et al., 2013).
During the early phase of reprogramming, exogenous pluripo-
tency factors likeOct4 can act as pioneer factors that bind to the
regulatory regions of many genes throughout the genome (Buga-
nim et al., 2013). Accumulating evidence has shown that plurip-
otency factors can interact with different epigenetic modulators
such as NuRD, BAF, or the PRC complex (Huang and Wang,
2014). Therefore, it is possible that the binding of exogenous
pioneer factors could recruit these epigenetic modulators and
facilitate the re-activation of epigenetically repressed lineage-
specific genes. This effect may be further strengthened by the
proper addition of compounds that regulate key signal pathways
or epigenetic modulators. On the other hand, exogenous plurip-
otency factors themselves may also act as lineage specifiers
during the early stages of the reprogramming process, because
it has been recently suggested that exogenous pluripotency fac-
tors may act as lineage specifiers during reprogramming to plu-
ripotency (Shu et al., 2013). Furthermore, the overexpression ofCell Stem Cell 16, February 5, 2015 ª2015 Elsevier Inc. 123
Table 2. Summary of Lineage Reprogramming in Humans since the Discovery of iPSCs
Initial Cell Population Target Cell Type Reprogramming Factors Reference
Fibroblasts Adipocytes (brown fat cells) PRDM16, CEBPb Kajimura et al., 2009
Endothelial cells Haematopoietic multipotent
progenitor cells
FOSB, GFI1, RUNX1, SPI1 Sandler et al., 2014
Fibroblasts Haematopoietic progenitors OCT4 Szabo et al., 2010
Fibroblasts Cardiac progenitors ETS2, MESP1 Islas et al., 2012
Fibroblasts Cardiomyocytes GATA4, HAND2, MYOCD, TBX5, miR-1, miR-133 Nam et al., 2013
Fibroblasts Cardiomyocytes GATA4, MEF2C, TBX5, MYOCD, MESP1 Wada et al., 2013
Fibroblasts Cardiomyocytes GATA4, MEF2C, TBX5, ESRRG, MESP1, Myocardin,
ZFPM2
Fu et al., 2013
Amniotic cells Endothelial Cells ETV2, FLI1, ERG1 (and TGFb inhibition) Ginsberg et al., 2012
Fibroblasts Hepatocytes HNF1A, HNF4A, HNF6, CEBPA, ATF5, PROX1,
p53-siRNA, C-MYC
Du et al., 2014
Fibroblasts Hepatocytes HNF1A, HNF4A, FOXA3, SV40 large T antigen Huang et al., 2014
Skin epithelial stem
cells
Limbal stem or progenitor cells PAX6 Ouyang et al., 2014
Fibroblasts Melanocytes MITF,SOX10,PAX3 Yang et al., 2014
Fibroblasts Monocyte-like progenitor cells SOX2, miR-125b Pulecio et al., 2014
Proximal tubule (HK2)
cell line
Nephron progenitors SIX1, SIX2, OSR1, EYA1, HOXA11, SNAI2 Hendry et al., 2013
Fibroblasts Neural crest cells SOX10 Kim et al., 2014
Fibroblasts Neural stem cells SOX2 Ring et al., 2012
Fibroblasts Neurons ASCL1, NGN2, CHIR99021, SB431542 Ladewig et al., 2012
Fibroblasts Neurons (glutamatergic) NGN2, Forskolin, Dorsomorphin Liu et al., 2013
Fibroblasts Neurons ASCL1 Chanda et al., 2014
Pericyte-derived cells Neurons SOX2, MASH1(also named ASCL1) Karow et al., 2012
Fibroblasts Neurons (dopaminergic) ASCL1, BRN2, MYT1L, LMX1A, FOXA2 Pfisterer et al., 2011
Fibroblasts Neurons (dopaminergic) ASCL1, LMX1A, NURRL Caiazzo et al., 2011
Fibroblasts Neurons (dopaminergic) MASH1, NGN2, SOX2, NURR1, PITX3 Liu et al., 2012
Fibroblasts Neurons (glutamatergic) ASCL1, BRN2, MYT1L, NEUROD1 Pang et al., 2011
Fibroblasts Neurons (glutamatergic) BRN2, MYT1L, miR-124 Ambasudhan et al., 2011
Fibroblasts Neurons (glutamatergic,
GABAergic)
ASCL1, MYT1L, NEUROD2, miR-9/9*, miR-124 Yoo et al., 2011
Fibroblasts Neurons (motor) BRN2, ASCL1, MYT1L, LHX3, HB9, ISL1, NGN2 Son et al., 2011
Fibroblasts Retinal pigment epithelium-like
cells
PAX6, RAX, CRX, MITF-A, OTX2, NRL, KLF4, C-MYC,
Activin A or RA + Shh treatment at later stages
Zhang et al., 2013
Pancreatic exocrine cells Pancreatic b-like cells Activated MAPK and STAT3 Lemper et al., 2014
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shown to induce differentiation (Loh and Lim, 2011). While the
exact mechanisms of pluripotency-factor-driven lineage conver-
sion still need further study, the potential presence of a transient
pluripotent state during the conversion process remains a
possibility. Although it has been shown that the expression of
endogenous pluripotency genes such as Nanog was low or
undetectable in these studies (Efe et al., 2011; Kim et al.,
2011a; Li et al., 2014a; Zhu et al., 2014b), more rigorous assays,
such as lineage tracing, are required to completely exclude this
possibility.
Exploration of the Molecular Mechanisms of Lineage
Reprogramming
To clarify the mechanism of lineage reprogramming, it is critical
to define how exogenous factors drive the conversion process
on the molecular level. Because the master genes of the target124 Cell Stem Cell 16, February 5, 2015 ª2015 Elsevier Inc.cell type are mostly epigenetically silenced in the initial cell pop-
ulation, an important question is how the regulatory network of
the target cell type is reactivated in reprogrammed cells during
conversion. Recently, significant insight has been gained from
the mechanistic analysis of iN cell induction from murine fibro-
blasts, which have been driven by the enforced expression of
Brn2, Ascl1, and Myt1l (BAM) (Wapinski et al., 2013). Wapinski
et al. (2013) determined that the genomic binding patterns of
Ascl1, a basic helix-loop-helix (bHLH) transcription factor, are
similar between fibroblasts and neural progenitor cells. They
further demonstrated that exogenousAscl1 binds to its authentic
neuronal target genes in fibroblasts at the early phase of iN cell
induction and facilitates the proper recruitment of other exoge-
nous factors, such as Brn2, to their binding sites in later stages.
Accordingly, Ascl1 acts as an ‘‘on-target pioneer factor’’ during
iN cell induction and can bind to its lineage-specific genomic
Figure 2. Factors Involved in Lineage
Reprogramming
Reprogramming factors, including lineage-spe-
cific transcription factors, small molecules,
epigenetic regulators, miRNAs, and pluripotency
factors, are manipulated to direct cell fate toward
the desired lineages. The ultimate downstream
effects of these factors are the re-establishment of
the GRN for the target cell type.
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cally activated or not (Zaret andCarroll, 2011). Therefore, Wapin-
ski et al. (2013) proposed a hierarchical mechanism responsible
for the BAM-factor-induced neuron conversion. Interestingly, the
reprogramming factors responsible for iPSC induction also have
pioneer properties (Soufi et al., 2012). In contrast to the pioneer
factor Ascl1, which can bind to its neural targets in fibroblasts
alone (Wapinski et al., 2013), the pluripotency factors Oct4,
Sox2, and Klf4 cooperatively function as pioneer factors; how-
ever, their initial binding regions in fibroblasts are largely different
from the regions in pluripotent stem cells (Buganim et al., 2013).
Thus, although one can hypothesize that, in general, pioneer fac-
tors play an important role during cell fate conversion, the exact
mechanism of these factors in lineage conversion may be cell
type dependent.
The use of factor combinations to induce lineage conversion
raises an important question: do different expression levels of
different exogenous factors affect the outcome of lineage re-
programming? Results from themechanistic analysis of iPSC re-
programming have provided evidence that factor stoichiometry
not only influences the reprogramming process but also the
quality of iPSCs (Carey et al., 2011; Papapetrou et al., 2009; Tie-
mann et al., 2011; Yamaguchi et al., 2011). For example, high
levels of exogenous Oct4 and Klf4 protein combined with low
levels of Sox2 and c-Myc resulted in the generation of high-qual-
ity iPSCs with the ability of generating mice through tetraploid
complementation (Carey et al., 2011). Accordingly, one can hy-
pothesize that factor stoichiometry may also influence the con-
version efficiency and functionality of converted cells in lineage
reprogramming. Interestingly, one recent report has shown
that higher levels of exogenous Mef2c with lower levels of
Gata4 and Tbx5 significantly enhanced cardiac reprogramming
efficiency (Wang et al., 2014), thus suggesting the important
role of factor stoichiometry in lineage reprogramming.
The mechanistic analysis of the conversion between cell types
could also benefit from other insights from iPSC reprogramming.
For example, a ‘‘seesaw’’ model for reprogramming has recently
been proposed by our group (Shu et al., 2013), in which a
balance that is established using pluripotency factors and/or
counteracting lineage specifiers can facilitate reprogramming
to pluripotency. Intriguingly, this model also proposed that devi-Cell Stem Cell 16ation from the balanced equilibrium for
pluripotency directs cells to flow into
divergent differentiated states. For
example, the classical pluripotency factor
Oct4 has been proposed to be a mesen-
dodermal lineage specifier that inhibits
ectodermal potential under certain condi-
tions in our model (Shu et al., 2013) andwas previously shown to induce mesodermal differentiation
when overexpressed in ESCs (Niwa et al., 2000). In lineage re-
programming, the overexpression of OCT4 alone drove the con-
version into mesodermal lineage hematopoietic cells (Szabo
et al., 2010). In contrast, strictly limited Oct4 expression at the
initial phase of reprogramming combined with constitutive
Sox2, Klf4, and c-Myc overexpression resulted in ectodermal
neural lineage conversion (Thier et al., 2012). Interestingly, early
studies on lineage switching within the blood system also
demonstrated transcription factor cross-antagonism during
these conversions (Heyworth et al., 2002; Nerlov and Graf,
1998). Collectively, these studies suggest that the balance be-
tween different lineage specifiers may play an important role in
the direction of cell fate conversion.
Strategies for Improving the Functional Maturation of
Converted Cells
The generation of functionally mature cells is fundamental to
many regenerative medical applications such as disease
modeling, drug development, and, particularly, cell therapy. In
principle, lineage reprogramming can generate functional cells
because this strategy can bypass the multiple steps of lineage
specification during development and directly convert one line-
age to another. However, the execution of this strategy for gener-
ating different types of fully functional mature cells, especially
terminally differentiated cells, remains a major challenge. For
instance, it has been recently demonstrated that in most studies,
directly converted cells fail to silence the expression programs of
the initial population, which strongly indicates that they possess
an immature phenotype (Cahan et al., 2014). As subsequently
discussed, the recent emergence of several novel strategies
may lead to the development of a fundamental solution for this
key issue in future studies.
Cell Fate Determination Factors May Not Be Sufficient for
Inducing Fully Functional Maturation. In most cases, reprog-
ramming factors are selected based on their importance in line-
age specification during embryonic development. Therefore, we
will refer to these factors as cell fate determination factors. How-
ever, it is unclear whether cell fate determination factors can also
prime the entire functional maturation network during lineage re-
programming. Several studies suggest that this may not work, at
least for the induction of certain cell types with multiple complex, February 5, 2015 ª2015 Elsevier Inc. 125
Figure 3. Emergence of a Novel Approach for the Generation of Functionally Mature Cells by Lineage Reprogramming
The generation of functionally mature cells by lineage reprogramming benefits from the combination of cell fate determination and maturation factors. In addition
to developmental clues, both cell fate determination and maturation factors can be identified through the comparison of global gene expression profiles in
immature fetal cells andmature adult cells. Further analysis of the GRN in these groups could facilitate the discovery of key cell fate determination andmaturation
factors responsible for cell fate conversion and functional maturation, respectively. Finally, the combination of cell fate determination and maturation factors can
convert the original cells into the desired cell type with fully functional maturation.
Cell Stem Cell
Reviewfunctions. For example, hepatocytes perform hundreds of func-
tions, including metabolic, synthetic, immunologic, and detoxifi-
cation processes (Bhatia et al., 2014), and may be one of the
most functionally complicated cell types. Mouse hepatocyte-
like cells induced by hepatic fate determination transcription fac-
tors remained functionally immature, which was reflected by the
incomplete hepatocyte differentiation and expression of certain
hepatoblast markers (Huang et al., 2011; Sekiya and Suzuki,
2011). Furthermore, an unexpected intestinal gene expression
program was detected in murine hepatocyte-like cells (Morris
et al., 2014). Similarly, the combination of hepatic cell determina-
tion factors HNF1A, HNF4A, and HNF6 could only induce hepa-
tocyte-like cells that lacked key functional features of human
hepatocytes (Du et al., 2014). Therefore, fate determination fac-
tors alone may not be sufficient to achieve functional maturation
of converted cells.
Combination of Cell Fate Determination and Maturation Factors.
Although several functional cell types, such as neuronal cells, can
be induced by lineage reprogramming using cell fate determina-
tion factors alone (Vierbuchen et al., 2010), the functional matu-
ration of other lineages, such as hepatocytes, may require
additional factors during lineage conversion. How to identify
such factors remains an important issue. In this regard, the induc-
tion of functional human hepatocytes may provide an example
(Du et al., 2014). To identify additional factors that promote
the functional maturation of hepatic-fate-determination-factor-
induced hepatocyte-like cells, we compared the global gene
expression patterns of induced cells, immature fetal hepato-
cytes, and freshly isolated primary human hepatocytes. This
approach led to the identification of threemature hepatocyte-en-
riched transcription factors: CEBPA, ATF5, and PROX1, which
we termed maturation factors. Intriguingly, the combination of
these maturation factors with cell fate determination factors re-
sulted in the induction of human induced hepatocytes (hiHeps),
which functionally reconstituted the central network of drug126 Cell Stem Cell 16, February 5, 2015 ª2015 Elsevier Inc.metabolism (Du et al., 2014). Importantly, the activities of key
drug metabolic enzymes, such as CYP3A4 in hiHeps, were also
comparable to freshly isolated primary human hepatocytes.
Moreover, these induced cells exhibited high levels of engraft-
ment in vivo (repopulating up to 30% of the recipient livers) and
secreted high levels of ALBUMIN comparable to that in primary
human hepatocytes. Considering that these key functional prop-
erties of hepatocytes were not observed in hepatic-fate-determi-
nation-factor-induced cells, the inclusion of hepatic maturation
factors in the factor combination plays a critical role in obtaining
hepatic drug metabolic function by lineage reprogramming.
The strategy to generate functional hiHeps may be instructive
for improvements in the function of converted cells fromother lin-
eages. Our findings suggest that fate determination and func-
tional maturation may be governed by different master genes
and are somewhat independent of each other. As a result, the
ectopic expression of cell fate determination factors may not
be sufficient to generate fully functional cells, and the addition
of functional maturation factors are required to promote this pro-
cess. Importantly, more recent studies have suggested that
these maturation factors could be identified through the analysis
of GRNs in adult functional target cell types (Morris et al., 2014).
Thus, we suggest that the combination of cell fate determination
and maturation factors may represent an effective approach to
achieve functional maturation by lineage reprogramming, which
may facilitate the induction of functionally mature cells of other
lineages (Figure 3). Furthermore, this strategy may also facilitate
the functional maturation of differentiated cells derived from
pluripotent stem cells, because previous studies showed that
the enforced expression of certain exogenous factors can pro-
mote the functional maturation of differentiated cells during the
directed differentiation process (Ionta et al., 2015; Kaneto et al.,
2005; Kyba et al., 2002; Martinat et al., 2006; Zhao et al., 2013).
Development of Functional Screening Assays. To identify the
optimal combination of factors for the induction of desired cell
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expression of lineage-specific markers is widely used as the in-
dicator for successful cell fate conversion, which has led to the
induction of a number of lineages such as neuronal cells and
cardiomyocytes (Ieda et al., 2010; Vierbuchen et al., 2010). How-
ever, there is a potential problem in this marker-based screening
approach, because the expression of lineage-specific markers
may not be directly linked to the function of converted cells.
Thus, factor combinations identified by this screening assay
may not result in fully functional mature cells. Therefore, the
development of novel screening assays directly based on cell
function is in high demand in this field.
Recently, a significant breakthrough has been achieved
toward the development of a functional screening assay for
generating transplantable hematopoietic stem cell (HSC) by
lineage reprogramming. Derrick Rossi and colleagues adopted
an elegant in vivo functional screening strategy by transplanting
cells transduced with HSC-enriched factors into lethally irradi-
ated congenic mice (Riddell et al., 2014). This strategy took
advantage of a unique feature of HSCs: that even one func-
tional HSC is capable of reconstituting the entire spectrum of
blood lineages in vivo. Indeed, all lineages of hematopoietic
progeny were detected in the recipient mice, which led to the
identification of 6 transcription factors Hlf, Runx1t1, Pbx1,
Lmo2, Zfp37, and Prdm5 that were required for the generation
of induced HSCs (iHSCs). This study illustrates how functional
screens can be applied to the induction of functionally compe-
tent cells. However, it is also notable that this in vivo functional
screening assay cannot be simply applied to the generation of
other lineages due to its reliance on this unique feature of
HSCs. To develop effective functional screening assays for
lineage reprogramming in other cell types, the development
and integration of novel technologies may be beneficial, and
these developed functional assays will likely need to be cell
type specific.
Creation of a Niche for the Functional Maturation of Converted
Cells. The maintenance of functional converted cells indepen-
dent of the overexpression of exogenous factors is a significant
issue for the successful generation of functional cells. For most
cell types, such as HSCs, the maintenance of functionality using
the culture medium alone is difficult because the essential fac-
tors or cellular signaling responsible for cell function mainte-
nance are not fully understood. One potential solution for this
dilemma is to co-culture the reprogrammed cells with supporting
cells from the endogenous niche where the target cells are main-
tained. For instance, in an attempt to induce human multipotent
progenitor cells (MPPs) from human umbilical vein endothelial
cells (HUVECs), Sandler et al. co-cultured HSC factor-trans-
duced HUVECs with engineered endothelial cells during conver-
sion, which mimicked the vascular microenvironment that
supports HSC specification during development (Sandler et al.,
2014). The combination of this niche with a serum-free medium
permitted the induction of hematopoietic-like colonies, which
serially engrafted in vivo and further differentiated into mature
blood cells including B cells. Collectively, these results suggest
the critical roles of the culture environment for the induction
and maintenance of functional converted cells, and the potential
use of supporting cells from the endogenous niche in the promo-
tion of cell functional maturation.Compared with the use of supporting cells in vitro, perhaps a
more effective way to promote cell functional maturation is to
take advantage of the in vivo niche, which has been adopted
to promote the further differentiation and functional maturation
of pancreatic progenitors derived from human ESCs (Kroon
et al., 2008). In principle, the in vivo niche can provide all essen-
tial factors that support the functional maintenance of target
cell types, thus facilitating functional lineage conversion. For
instance, although the induction of murine cardiomyocyte-like
cells by the overexpression of Gata4,Mef2c, and Tbx5 was inef-
ficient in vitro (Ieda et al., 2010), the overexpression of the same
three factors in murine cardiac fibroblasts in vivo resulted in the
robust generation of functional cardiomyocyte-like cells (Qian
et al., 2012); this finding suggests the importance of the in vivo
niche during the conversion process.
Induction of Lineage Subtypes with Specific Function. For
target lineages composed of cell subtypes, the induction of a
generic lineage-specific phenotype by exogenous factors is typi-
cally not sufficient for the generation of fully mature converted
cells with diversified functions. In this regard, the induction of
the neuronal lineage, which is constituted by a vast array of
regional specific neuronal subtypes, may offer an instructive
example. Although the originally identified neural factor combi-
nation BAM can convert fibroblasts into iN cells with basic
neuronal functional features (Vierbuchen et al., 2010), the con-
verted cells often exhibit glutamatergic neuronal properties,
which have limited applicative potentials in the studies of neural
diseases caused by certain neuronal subpopulations, such as
Parkinson’s disease. Consequently, different functional neuronal
subtypes have been generated using lineage reprogramming,
including dopaminergic (DA) neurons and motor neurons (MNs)
(Caiazzo et al., 2011; Kim et al., 2011b; Liu et al., 2012; Pfisterer
et al., 2011; Sheng et al., 2012a; Son et al., 2011). These iN sub-
types not only possess fundamental neuronal functional proper-
ties but also exhibit subtype-specific functional features that
resemble their in vivo counterparts such as the secretion of
dopamine in DA neurons (Caiazzo et al., 2011; Kim et al.,
2011b; Liu et al., 2012).
Notably, the addition of subtype-specific factors to factors
that induce the generic neuronal conversion has been shown
to induce neuronal subtypes. For instance, the combination of
BAM factors and subtype-specific transcription factors that
regulate motor neuron development enabled the induction of
functional motor neurons from mouse and human fibroblasts
(Son et al., 2011). This approach may facilitate the generation
of subtypes in other lineages, thereby combining the factors
that are responsible for generic lineage induction and subtype-
specific factors. Considering that the functional heterogeneity
of cell subtypes is a common phenomenon for multiple lineages,
such as cardiomyocytes and hepatocytes (Evans et al., 2010;
Gebhardt, 1992), the induction of functional lineage subtypes
could have many applications for solving the functional matura-
tion problem for a broad panel of lineages other than neuronal
cells.
Advances in the Optimization of Assays for Induced Cell
Characterization
Comparison with Primary Isolated Cells. One of the most crit-
ical issues in lineage reprogramming is to evaluate the similarity
between the converted cells and the target cell type. Currently,Cell Stem Cell 16, February 5, 2015 ª2015 Elsevier Inc. 127
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of target cell type as the positive control (Du et al., 2014; Huang
et al., 2014; Riddell et al., 2014; Zhou et al., 2008), whichmakes it
relatively difficult to compare the function of converted cells
generated from different studies. Furthermore, the in vitro culture
conditions for most somatic cell types are sub-optimized; thus,
the cultivation of these positive controls may lead to the loss of
their original features, which makes them inappropriate as a
reference for converted cells. For instance, hepatic features
can be quickly lost upon prolonged cultivation or undergoing
the freeze-thaw cycle. Instead, freshly isolated primary hepato-
cytesmaintainmost features of the in vivo hepatocytes, andmix-
ing these cells from different individuals can further reduce the
potential variation caused by their heterogeneity of the genetic
background. Accordingly, mixtures of freshly isolated primary
hepatocytes from different individuals were used as the positive
controls for hiHeps (Du et al., 2014). This example may show the
importance of selecting proper positive controls for the evalua-
tion of induced cell types by lineage reprogramming. In addition,
proper positive controls can also facilitate the optimization of
protocols for lineage induction, which serves as a reference for
different reprogramming conditions.
Development of Novel Assays for the Analysis of Converted Cell
Features. Different methods have been applied to the evalua-
tion of converted cells (Cohen and Melton, 2011), such as the
analysis of marker gene expression, global gene expression
and epigenetic patterns, the silencing of exogenous factors,
and the epigenetic state of master genes. However, these as-
says are primarily based on the whole cell population, which
cannot reveal the heterogeneity of converted cells. In this regard,
single-cell analysis provides an important tool to address this
issue, which has been used in the characterization of iN cells
and iHSCs (Marro et al., 2011; Riddell et al., 2014). Currently,
single-cell analysis is mainly used to analyze the expression of
key marker genes in individual cells. However, further deep anal-
ysis that includes a highly multiplexed quantitative analysis and
single-cell RNA sequencing could provide additional information
on gene expression variation in the converted cells. These
techniques have been applied to the analysis of mouse hemato-
poietic cells and human preimplantation embryos (Guo et al.,
2013; Yan et al., 2013).
Another important issue is how to quantitatively define the
extent of the similarities between the converted cells and their
in vivo counterparts; this question is relatively difficult to address
using current methodology for the characterization of induced
lineages. More recently, a major advance toward this goal has
been made via the construction of a novel network biology plat-
form referred to as CellNet (Cahan et al., 2014). Using 3,419 pub-
licly available gene expression profiles of diverse cell types and
tissues, the groups of James Collins and George Daley recon-
structed the GRN for 20 cell types and tissues, which can be
scored. As a result, they could not only quantitatively compare
the directly converted cells with their in vivo counterparts, but
also improve the quality of converted cells by spotting the aber-
rant GRN (Morris et al., 2014). Figuratively, the application of
GRN analysis in lineage reprogramming has provided a ‘‘global
positioning system’’ for the induction of functional cells in regen-
erative medicine, which not only tells us how far the ‘‘distance’’ is
between the induced cells and their in vivo counterparts but also128 Cell Stem Cell 16, February 5, 2015 ª2015 Elsevier Inc.shows how to drive the partially induced cells toward their in vivo
counterpart. Remarkably, this strategy offers a blueprint for en-
gineering cell identity that could be widely applied to both line-
age reprogramming and directed differentiation. However,
several limitations of this platform remain, such as the inability
to distinguish cell subtypes and cellular heterogeneity. The com-
bination of single-cell expression profiling andGRN analysis may
provide a solution for these current limitations in future studies.
Evaluation of Cell Function In Vivo. For the analysis of con-
verted cell function, the most stringent test is to evaluate their
function in vivo. In general, the assessment of the ability of con-
verted cells to survive and integrate into the in vivo environment
is typically the first step. Although this assay has been done on
several murine lineages induced by lineage reprogramming (Bre-
denkamp et al., 2014; Han et al., 2012; Huang et al., 2011; Kim
et al., 2011b; Hiramatsu et al., 2011; Najm et al., 2013;
Riddell et al., 2014; Ring et al., 2012; Sekiya and Suzuki, 2011;
Son et al., 2011; Thier et al., 2012; Yang et al., 2013), only a
few induced human cell types have been transplanted in vivo
and have shown the ability of surviving and integrating into the
in vivo environment such as hepatocytes (Du et al., 2014; Huang
et al., 2014; Zhu et al., 2014b), multipotent hematopoietic pro-
genitors (Sandler et al., 2014), neural crest cells (Kim et al.,
2014), limbal stem cells (LSCs) (Ouyang et al., 2014), and endo-
thelial cells (Ginsberg et al., 2012).
The in vivo function of converted cells can be further tested us-
ing animal disease models. One representative example is the
functional evaluation of induced thymic epithelial cells (TECs)
from mouse fibroblasts via the enforced expression of Foxn1
(Bredenkamp et al., 2014). The transplantation of induced TECs
led to the formation of a complete, fully organized, and functional
thymus in vivo, which supported T cell development in the athy-
mic nude mice (Bredenkamp et al., 2014). Although these func-
tional assays have been used as an important reference to
assess the functionalmaturation of converted cells, the complete
elimination of target cells is often unachievable, and the in vivo
environment is more complicated than in vitro conditions. Thus,
positive outcomes that may be the result of multiple factors
such as re-proliferation of residual target cells or the instructive
effects that result from other cell types, both of which are not
directly related to the function of the converted cells, should be
interpreted cautiously. Furthermore, additional attention must
begiven to the animalmodel itself in the evaluation of humancon-
verted cells. The xeno-rejection response and the interspecific
difference between animals and humans may play important
roles during the transplantation of converted human cells.
Strategies to Produce Large Numbers of Induced Cells
for Translational Purposes
Complementary to the iPSC technology, functional cells gener-
ated by lineage reprogramming are, in principle, expected to
be widely used for biomedical applications, including disease
modeling, drug development, and cell therapy (Vierbuchen and
Wernig, 2011). However, one major limitation of conventional
direct lineage conversion is that converted terminal functional
cells typically have poor proliferative ability, which is a major bar-
rier for applicative purposes that require large cell numbers.
Recently, several novel strategies have been developed to
resolve this problem (Figure 4). One emerging solution is to
generate proliferative stem cells or progenitors/precursors by
Figure 4. Novel Strategies for Large-Scale
Induction of Lineage Conversion for
Application Purposes
To generate a large number of converted cells
for application purposes, somatic cells can be
induced into stem cells or progenitor/precursors
and propagated prior to further differentiation into
terminally differentiated cells. Another strategy is
to induce a transient proliferating intermediate
state during lineage conversion, and these in-
termediates can gradually stop proliferation and
become functional terminal cells.
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tors/precursors are more desirable for transplantation because
they can efficiently engraft and integrate into the in vivo microen-
vironment. Recently, a number of stem cells or progenitors/
precursors have been induced by lineage reprogramming such
as neural stem cells or progenitors (Han et al., 2012; Kim et al.,
2011a; Lujan et al., 2012; Ring et al., 2012; Sheng et al.,
2012b; Thier et al., 2012), oligodendrocyte precursor cells
(Najm et al., 2013; Yang et al., 2013), hepatic stem cells (Yu
et al., 2013), HSCs (Riddell et al., 2014), and hematopoietic multi-
potent progenitors (Sandler et al., 2014). Notably, several types
of stem cells or progenitors/precursors, such as neural stem
cells or progenitors, have been shown to proliferate in vitro
(Han et al., 2012; Kim et al., 2011a; Lujan et al., 2012; Ring
et al., 2012; Sheng et al., 2012b; Thier et al., 2012), which sug-
gests the potential of these cells for large-scale use.
In addition to the direct induction of stem cells or progenitors/
precursors, another emerging potential strategy for obtaining
large numbers of converted cells is to create a transient prolifer-
ative intermediate state during lineage conversion, which has
been shown in the induction of human hepatocytes (Du et al.,
2014). To overcome proliferation arrest and cell death during he-
patic conversion, we employed C-MYC overexpression and P53
knockdown in combination with the overexpression of hepatic
transcription factors during the induction process. Strikingly,
the inclusion of exogenous C-MYC and P53 small interfering
RNAs permitted the induction of proliferative intermediates
with high expansion ability, which enabled a greater than 106-
fold increase in cell number (Du et al., 2014). These intermediates
can further become functionally mature upon the silencing of
exogenous factors, which can lead to the production of large
numbers of hepatocytes sufficient for applicative purposes
such as drug discovery. It would be interesting to determine
whether these factors can also be applied to the induction of
transient proliferative intermediates during the induction of other
cell types in the future.
Translation of Lineage Reprogramming toward Cell
Therapy
Undoubtedly, the most exciting potential application of lineage
reprogramming is cell replacement therapy (Figure 5). Several
recent studies have, in principle, demonstrated the potentialCell Stem Cell 16use of this strategy for generating cells
for therapeutic purposes. To develop a
novel approach for the treatment of
corneal surface diseases, Ouyang et al.
(2014) induced human LSCs from skinepithelial stem cells via the overexpression of PAX6 , which
can differentiate into cornea epithelial cells (CECs) in vivo.
Impressively, when transplanted onto eyes in a rabbit corneal
injury model, these reprogrammed LSCs could replenish CECs
and repair the damaged corneal surface (Ouyang et al., 2014).
Therefore, combined with novel strategies that expand con-
verted cells as previously discussed, the induction of cells with
therapeutic potential by direct conversion could be applied for
clinical transplantation in the future.
Compared with the directed differentiation from pluripotent
stem cells, lineage reprogramming has one obvious advanta-
geous feature in that it can be conducted in vivo. The in vivo
execution of this strategy could theoretically avoid the risk of
teratoma formation and genetic mutations caused by long term
in vitro culture. Furthermore, in vivo lineage reprogramming
could also bypass the difficulties of transplantation, which is a
potential problem in the application of cells induced in vitro by
directed differentiation or lineage reprogramming. Finally, natu-
ral lineage conversions have been observed in vivo, such as
the transdifferentiation of pancreatic a or d cells into b cells after
near-total b cell loss (Chera et al., 2014; Thorel et al., 2010). As a
result, in vivo lineage reprogramming may represent a direct and
simple approach to generating functional cells for replacement
therapy.
Inspiringly, an increasing number of reports have demon-
strated that lineage reprogramming can be achieved in vivo
(Guo et al., 2014; Inagawa et al., 2012; Jayawardena et al.,
2012; Li et al., 2014b; Mathison et al., 2012; Montana et al.,
2013; Niu et al., 2013; Qian et al., 2012; Rouaux and Arlotta,
2013; Song et al., 2012; Torper et al., 2013; Zhou et al., 2008).
Recently, it has been reported that glial cells, especially astro-
cytes, can be converted into functional neuroblasts or neurons
in vivo (Guo et al., 2014; Niu et al., 2013; Torper et al., 2013).
For instance, in Alzheimer’s disease mouse models, Guo et al.
(2014) successfully reprogrammed reactive glial cells into func-
tional neurons, suggesting a potential application of in vivo
reprogramming for brain repair. The recent induction of cardio-
myocytes from cardiac fibroblasts in vivo is another step in the
efforts that aim to develop novel therapies using in vivo lineage
reprogramming (Qian et al., 2012; Song et al., 2012). Through
the delivery of the cardiac reprogramming factors into themouse, February 5, 2015 ª2015 Elsevier Inc. 129
Figure 5. In Vivo Lineage Reprogramming
for Cell Therapy
Reprogramming factors can be delivered into the
target in vivo site to induce the conversion of so-
matic cells into the desired cells, thereby repairing
the impaired tissue in situ. The advantages and
challenges of this strategy are highlighted.
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approximately 35% of the cardiomyocytes in the border/infarct
zonewere induced from cardiac fibroblasts. Importantly, cardiac
function was significantly improved in reprogramming-factor-in-
fectedmice compared with controls. In another study performed
by Song et al. (2012), cardiomyocyte-like cells were induced
from endogenous cardiac fibroblasts by lineage reprogramming
in the injured heart. Cardiac function was enhanced by the injec-
tion of reprogramming factors compared with control mice.
Although these studies have, in principle, demonstrated that
in vivo lineage reprogramming has therapeutic effects in disease
models, the exact role of the in situ converted cells during this
process remains unknown and requires further exploration of
the mechanism for the observed therapeutic effects.
Despite great promise for the treatment of diseases, the in vivo
application of lineage reprogramming must still overcome
several major hurdles. For instance, a safe and efficient delivery
method must be established for the delivery of the reprogram-
ming factors to the targeted in vivo sites. Avoidance of the off-
target effects of reprogramming factors in vivo is also an
important issue, because these effects may induce unwanted
cells. Finally, the potential side effects of in vivo reprogramming
must be studied in detail and further excluded. For example, the
potential risk of arrhythmias may arise if the cardiomyocytes
generated by the in vivo reprogramming approach exhibit elec-
trical heterogeneity (Xu et al., 2012).
Perspectives
With rapid progress that includes not only the identification of
new factors but also the development of novel strategies for
the generation of functionally mature cells, the initial stage of
studies in lineage reprogramming that focused on demonstrating
the feasibility of this strategy has passed. Now, we are progress-
ing toward the next generation of lineage reprogramming for
which a systematic guidebook for engineering different cellular
states is progressively being built. Although it was originally
thought to be difficult to scale up the cells generated by lineage
reprogramming (Vierbuchen and Wernig, 2011), emerging ap-
proaches, such as the conversion into proliferative stem cells
or progenitors/precursors and the induction of expandable tran-
sient intermediates, permit the potential use of lineage reprog-
ramming for biomedical applications that require a large number
of cells. These significant advances have undoubtedly made130 Cell Stem Cell 16, February 5, 2015 ª2015 Elsevier Inc.lineage reprogramming a complementary
strategy for directed differentiation from
pluripotent stem cells for providing cell
resources for regenerative medicine.
Although the field of lineage reprog-
ramming has progressed rapidly in recent
years, it is obvious that it still facesseveral key challenges for its use in both research and therapeu-
tic applications. First, the functional maturation of converted
cells remains a fundamental issue for the entire field. In general,
the acquisition of functional features is a slow and inefficient pro-
cess that results in functional heterogeneity of the converted
cells. Thus, significant work is needed to optimize current proto-
cols for the production of fully functional cells with a highly purity.
Second, more efficient and robust strategies for converting
mature cell types require a better understanding of the mecha-
nism of lineage reprogramming. Answers to these questions
will facilitate the generation of functionally mature cells and will
benefit by developing our understanding of the principles of
cell fate determination. Finally, for therapeutic purposes, sub-
stantially safer approaches are required that will avoid genetic
manipulation and the use of animal-derived factors. In this re-
gard, the use of small molecules for developing chemically
defined protocols would be one promising way for the clinical
application of lineage reprogramming. It is also essential to
develop detailed global analysis to guarantee the integration
and fidelity of converted cells to their in vivo counterparts on ge-
netic and epigenetic levels. Once the challenges previously dis-
cussed are overcome, we anticipate that lineage reprogramming
will ultimately enable the generation of any desired cell state both
in vitro and in vivo as well as the recapitulation of complex tis-
sues that consist of multiple lineages in the future.
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